ABSTRACT
Background Treatment of locally advanced esophageal cancer includes neoadjuvant chemoradiation (chemoRT) and esophagectomy. We evaluated perioperative and oncologic outcomes among patients who received neoadjuvant chemoRT and immunotherapy (I/O).
Methods Adults who underwent esophagectomy following neoadjuvant chemoRT or chemoRT+I/O for T1-4, N0-3, M0 esophageal cancer were identified from the National Cancer Database (2012-2020). Unadjusted, propensity score-matched, and Cox proportional hazards analyses compared perioperative outcomes and three-year overall survival (OS) between neoadjuvant chemoRT versus chemoRT+I/O cohorts.
Results Among 17,937 patients, 261 (1.5%) received neoadjuvant chemoRT+I/O. ChemoRT+I/O patients were younger (62 versus 64 years, p=0.002) and had a longer interval between chemotherapy and surgery (104.5 versus 97.0 days, p<0.001) compared with chemoRT patients. Among the chemoRT+I/O cohort, there were more undifferentiated tumors (46.4% versus 34.3%, p<0.001) with adenocarcinoma histology (93.9% versus 81.2%, p<0.001) compared with the chemoRT cohort. On unadjusted analysis, there were no significant differences regarding margin positivity, 30-day readmission, 30-day mortality, or 90-day mortality. ChemoRT+I/O patients had higher 3-year OS (61.4% 95%CI [54.2-67.7] versus 55.1% [54.3-55.9], p=0.02), more lymph nodes resected (median 17.0 IQR [11.0-25.0] versus 15.0 [10.0-22.0], p=0.007), and less pathologic nodal downstaging from N2 to N1/N0 (36.8% vs 48.4%, p<0.001) than chemoRT patients. Propensity score-matched analyses (n=217) revealed no differences in perioperative outcomes and 3-year OS (65.0% 95%CI [57.1-71.8] versus 56.0% [48.0-63.3], p=0.11) between the chemoRT+I/O and chemoRT cohort.
Conclusions There were similar perioperative outcomes and 3-year OS between patients who received neoadjuvant chemoRT+I/O and chemoRT, supporting the feasibility of adding immunotherapy to neoadjuvant regimens.
Competing Interest Statement
SJK has served a consultant/advisory role for Astellas, Daiichi-Sankyo, Merck, Bristol Myers Squibb, Eli Lilly, Sanofi-Aventis, Natera, and AstraZeneca. SJK reports stock ownership in Turning Point Therapeutics.
Funding Statement
The authors and affiliated institutions did not receive funds of any kind for this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Cancer Database (https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/) updated to 2020.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Meeting Presentation: Data included in this manuscript were presented in a podium presentation at the 2022 Society of Thoracic Surgeons annual meeting.
Source of Funding: The authors and affiliated institutions did not receive funds of any kind for this submission.
Conflicts of Interest: SJK has served a consultant/advisory role for Astellas, Daiichi-Sankyo, Merck, Bristol Myers Squibb, Eli Lilly, Sanofi-Aventis, Natera, and AstraZeneca. SJK reports stock ownership in Turning Point Therapeutics.
Data Availability
All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript All data produced are available online at https://www.dropbox.com/scl/fo/2wyeihroquc88a09ftvgw/h?rlkey=brt8cumkb3yo87rs8d87bqcty&dl=0
https://www.dropbox.com/scl/fo/2wyeihroquc88a09ftvgw/h?rlkey=brt8cumkb3yo87rs8d87bqcty&dl=0
